

해외 바이오의약품 임상 현황 (2020.3.2~2020.3.8)

한국바이오의약품협회, 2020.3.10.
출처: ClinicalTrials.gov

○ 미국 11건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04298138	Dengue 3 Human Infection Model (DENV-3)	Dengue	Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)	State University of New York - Upstate Medical University Walter Reed Army Institute of Research (WRAIR) U.S. Army Medical Research and Development Command	Phase 1
NCT04283461	Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection	Corona Virus Infection	Biological: mRNA-1273	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04254627	Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness (GWI)-Associated Multi-symptom Disease Homeostasis Reset	Gulf War Illness	Drug: Etanercept Drug: Mifepristone	Nova Southeastern University RTI International Rochester General Hospital	Phase 1
NCT04242498	A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa	Hidradenitis Suppurativa	Drug: Bimekizumab Other: Placebo	UCB Biopharma SRL UCB Pharma	Phase 3
NCT04196010	G-CSF and Continuous Infusion Chemotherapy (CI-GCLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms	Myeloid Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia	Drug: Cladribine Drug: Cytarabine Biological: Granulocyte Colony-Stimulating Factor Drug: Mitoxantrone	University of Washington National Cancer Institute (NCI)	Phase 1
NCT04160195	T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma	Lymphoma, B-Cell Lymphoma, Non-hodgkins Chronic Lymphocytic Leukemia B-Cell Chronic Lymphocytic Leukemia	Biological: Anti-CD19-CAR and Anti-CD20-CAR T cells Drug: Cyclophosphamide Drug: Fludarabine	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1
NCT04078022	Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine	Shigella	Biological: SF2a-TT15 Shigella Vaccine Other: Placebo Biological: S. flexneri 2a strain 2457T Challenge Agent	University of Maryland, Baltimore	Phase 2
NCT04038619	Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients	Colitis Diarrhea Malignant Genitourinary System Neoplasm	Procedure: Fecal Microbiota Transplantation Drug: Loperamide	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04091750	Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma	Melanoma	Drug: Nivolumab Drug: Ipilimumab Drug: Cabozantinib	Georgetown University MedStar Franklin Square Medical Center Hackensack Meridian Health Exelixis	Phase 2
NCT04270942	At-Risk for Type 1 Diabetes Extension Study	Diabetes Mellitus, Type 1	Biological: teplizumab	Provention Bio, Inc.	Phase 2
NCT04262154	Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer	Metastatic Prostate Cancer	Drug: Atezolizumab Drug: Abiraterone Drug: Prednisone Drug: Lupron Radiation: Stereotactic Body Radiotherapy (SBRT)	Memorial Sloan Kettering Cancer Center Genentech, Inc.	Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04015180	Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04262661	A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes	Healthy Volunteers Diabetes Mellitus, Type 2	Drug: NNC0472-0147 Drug: insulin glargine Drug: Placebo (NNC0472-0147)	Novo Nordisk A/S	Phase 1
NCT04205552	Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients	NSCLC Stage II NSCLC, Stage IIIA NSCLC, Stage I	Drug: Nivolumab 10 MG/ML Intravenous Solution Drug: Relatlimab 10 MG/ML Intravenous Solution	University Hospital, Essen	Phase 2
NCT04015180	Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04246489	Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer	Uterine Cervical Neoplasms	Drug: Bintrafusp alfa	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04261335	The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy	Hypoxia-Ischemia, Brain	Biological: CL2020 cells	Nagoya University Life Science Institute, Inc.	Phase 1
NCT04015180	Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090	Retinopathy of Prematurity (ROP)	Drug: Eylea (Aflibercept, BAY86-5321) Procedure: Laser photocoagulation	Bayer	Phase 3
NCT04246489	Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer	Uterine Cervical Neoplasms	Drug: Bintrafusp alfa	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2